The Secondary Prevention of myocardial infarction by drug treatment; excluding lipid lowering agents

References

• Kjekshus J K. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F–49F
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320–331
   PubMed Web of Science ®Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 1: 397–402
   PubMed Web of Science ®Google Scholar
• MacMahon S, Collins R, Knight C, Yusuf S. Reduction in major morbidity and mortality by heparin in acute myocardial infarction (abstract). Circulation 1988; 78(suppl II)II–389
   Google Scholar
• Miller G J. Antithrombotic Therapy in the Primary Prevention of Acute Myocardial Infarction. Am J Cardiol 1989; 64: 29B–32B
   PubMed Web of Science ®Google Scholar
• The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–7
   PubMed Web of Science ®Google Scholar
• B-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results. JAMA 1982; 247: 1707–14
   PubMed Web of Science ®Google Scholar
• The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). Am J Cardiol 1985; 56: 1G–57G
   PubMed Web of Science ®Google Scholar
• Hansteen V, Moinichen E, Lorentsen E, et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J 1982; 284: 155–160
   PubMed Web of Science ®Google Scholar
• Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction. An overview of the randomized trials. Prog Cardiovasc Dis 1985; 17: 335–371
   Web of Science ®Google Scholar
• Boissel J P, Leizorovicz A, Picolet H, Peyrieux J C. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol 1990; 66: 251
   PubMed Web of Science ®Google Scholar
• Lithell H OL. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203–209
   PubMed Web of Science ®Google Scholar
• Rosman J, Weidmann P, Ferrari P. Antihypertensive drugs and serum lipoproteins. “Lipoprotein Metabolism and Lipid-Lowering Therapy: The State of the Art”, D J Betteridge, G A MacGregor, P S Sever. Gardiner-Caldwell Communications Ltd, Macclesfield 1990; 129–139
   Google Scholar
• Kostis J B, Rosen R C. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. Circulation 1987; 75(1)204–212
   PubMed Web of Science ®Google Scholar
• Ablad B, Ryden L. 1991, Personal Communication
   Google Scholar
• La Rovere M T, Specchia G, Mortara A, Schwartz P J. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction: a prospective study. Circulation 1988; 78: 816–824
   PubMed Web of Science ®Google Scholar
• The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990; 66: 779–785
   PubMed Web of Science ®Google Scholar
• The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984; 5: 516–528
   PubMed Web of Science ®Google Scholar
• The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–392
   PubMed Web of Science ®Google Scholar
• Held P H, Yusuf S, Furberg C D. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J 1989; 299: 1187–1192
   PubMed Web of Science ®Google Scholar
• Conway M, Mohideen R, Adamopoulos S, Flather M, Collins R, Sleight P. A dose-finding study for the initiation of captopril within 24 h of acute myocardial infarction. (Pre-pilot study for ISIS-4). Quart J Med 1989; 70–73: 973–974
   Google Scholar
• ISIS Pilot Study Collaborators' Group. Randomised double-blind trial of oral captopril and of oral nitrates in suspected acute myocardial infarction: safety and practicability. Eur Heart J 1990; 11(Suppl)352
   Google Scholar
• Pipilis A, Flather M, Collins R, Conway M, Sleight P. ISIS-4 pilot study: serial hemodynamic changes with oral captopril and oral isosorbide mononitrate in a randomized double-blind trial in acute myocardial infarction. J Am Coll Cardiol 1991; 17: 115A
   Google Scholar
• Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; i: 255–259
   Google Scholar
• Jugdutt B I, Warnica J W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage and infarct location. Circulation 1988; 78: 906–919
   PubMed Web of Science ®Google Scholar
• Steinberg D, Parthasarathy S, Carew T E, Khoo J C, Witztum J L. Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915–924
   PubMed Web of Science ®Google Scholar
• Horwitt M K. Data supporting supplementation of humans with vitamin E. J Nutr 1991; 121: 424–429
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S, Hebert P, Fiebach N H, Eberlein K A, Godwin J, Qizilbash N, Taylor J O, Hennekens C H. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38
   PubMed Web of Science ®Google Scholar
• Cruickshank J M, Thorp J M, Zacharias F J. Benefits and potential harm of lowering high blood pressure. Lancet 1987; i: 581–84
   Google Scholar
• Sleight P. Blood pressures, hearts, and U-shaped curves. Lancet 1988; i: 235
   Google Scholar
• The BBPP Research Group. The Beta-Blocker Pooling Project (EBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9: 8–16
   Web of Science ®Google Scholar